$161 Million is the total value of Essex Woodlands Management, Inc.'s 6 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q3 2019 | ||||||||
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-11-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MEDICINOVA INC | 45 | Q2 2024 | 6.5% |
| REVANCE THERAPEUTICS INC | 42 | Q2 2024 | 44.6% |
| AXOGEN INC | 26 | Q4 2021 | 43.3% |
| ENDOLOGIX INC | 24 | Q1 2019 | 22.5% |
| ABIOMED INC | 20 | Q1 2018 | 52.1% |
| CORIUM INTL INC | 20 | Q1 2019 | 23.5% |
| TELA BIO, INC. | 19 | Q2 2024 | 31.5% |
| VENUS CONCEPT, INC. | 17 | Q4 2023 | 21.3% |
| EYEPOINT PHARMACEUTICALS INC | 15 | Q2 2024 | 27.6% |
| ACURA PHARMACEUTICALS INC | 15 | Q1 2019 | 1.4% |
View Essex Woodlands Management, Inc.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-30 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View Essex Woodlands Management, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.